

Willingness to start insulin therapy among insulin-naïve persons with type 2 diabetes mellitus at Gulu Regional Referral Hospital, Gulu City, Uganda

Brenda Nakitto, Moses Opedo, Federes Nansubuga, Edward Omondi, Emmanuel Musinguzi, Edwin Cleopas Otile, Steven Ekak, Christine Nannungi, Paska Apiyo, Pebalo Francis Pebolo and Felix Bongomin 

Ther Adv Chronic Dis

2024, Vol. 15: 1–11

DOI: 10.1177/
20406223241247650

© The Author(s), 2024.
Article reuse guidelines:
[sagepub.com/journals-
permissions](https://sagepub.com/journals-permissions)

Abstract

Background: Most patients with type 2 diabetes mellitus (DM2) will require insulin for glycemic control during their disease.

Objectives: We evaluated the willingness to start insulin therapy among insulin-naïve persons with DM2 in urban Northern Uganda.

Design: A facility-based, quantitative, cross-sectional study was conducted between June and August 2023 recruiting insulin-naïve type 2 diabetes mellitus patients attending routine health care at Gulu Regional Referral Hospital, Gulu, Uganda.

Methods: We gauged participants' willingness to use insulin by asking, 'If your doctor prescribed insulin for you, would you accept to use it?' with responses categorized as either 'Yes' or 'No'. Poisson regression analysis was performed to assess the factors associated with willingness to start insulin therapy. $p < 0.05$ were considered statistically significant.

Results: We enrolled 190 participants, with a mean age of 55 ± 12.72 years. Most participants were female (63.7%, $n = 121$), attained a primary level of education (70.0%, $n = 133$), and were unemployed (84.2%, $n = 160$). Overall, 73.4% ($n = 138$) of the participants were willing to receive insulin therapy if indicated. Participants recently advised on insulin showed a 34% higher willingness [adjusted prevalence ratio (aPR): 1.34, 95% confidence interval (CI): 1.06–1.72, $p = 0.007$], whereas those with a disease duration of 6 years or more were 43% less willing (aPR: 0.57, 95% CI: 0.39–0.81, $p = 0.002$) and those concerns about coping with insulin therapy were 55% less willing to commence insulin therapy (aPR: 0.57, 95% CI: 0.39–0.81, $p = 0.002$).

Conclusion: About three in every four participants with DM were willing to receive insulin if indicated. However, healthcare providers should consider personalized counseling strategies to alleviate concerns and enhance informed decision-making regarding insulin initiation. Future interventions should focus on addressing specific barriers associated with prolonged disease duration and apprehensions related to insulin therapy to optimize glycemic control in this population.

Correspondence to:

Felix Bongomin
Faculty of Medicine, Gulu
University, P.O. Box 166,
Gulu, Uganda

Department of Internal
Medicine, Gulu Regional
Referral Hospital, P.O.
Box 160, Gulu, Uganda
drbongomin@gmail.com

Brenda Nakitto
Moses Opedo
Federes Nansubuga
Edward Omondi
Emmanuel Musinguzi
Edwin Cleopas Otile
Steven Ekak
Christine Nannungi
Pebalo Francis Pebolo
Faculty of Medicine, Gulu
University, Gulu, Uganda

Paska Apiyo
Department of Internal
Medicine, Gulu Regional
Referral Hospital, Gulu,
Uganda

Plain language summary

Exploring readiness for insulin treatment in people with type 2 diabetes at Gulu Regional Referral Hospital, Uganda

In this study, we investigated the willingness to start insulin therapy among individuals with type 2 Diabetes Mellitus (DM2) in urban Northern Uganda. Understanding the

importance of insulin for glycemic control in DM2, we surveyed 190 participants at Gulu Regional Referral Hospital. We found that more than three-quarters of the participants expressed a willingness to receive insulin therapy if recommended. Factors influencing this willingness included recent advice on insulin, which was associated with a 34% higher likelihood of acceptance. Conversely, individuals with a disease duration of 6 years or more were 43% less willing, and those concerned about coping with insulin therapy were 55% less willing to commence treatment. These findings underscore the need for healthcare providers to offer personalized counseling strategies, addressing specific concerns, to facilitate informed decision-making regarding insulin initiation. Looking ahead, interventions should prioritize overcoming barriers related to prolonged disease duration and apprehensions about insulin therapy to optimize glycemic control and improve the well-being of individuals with DM2 in this population.

Keywords: diabetes mellitus, Gulu, insulin naïve, willingness

Received: 23 November 2023; revised manuscript accepted: 1 April 2024.

Introduction

Globally, the number of people with diabetes mellitus (DM) has increased four times in the past 30 years making it the ninth major cause of death.¹ The most prevalent DM is type 2 (DM2) affecting an estimated 90–95% of the global 8.5% adult population with DM.² Almost 10% of adults now have DM.³ Sub-Saharan Africa has witnessed a significant increase in the prevalence of DM2 of 4.3% in 2012 compared with a current global prevalence of 6.4% in the last 50 years.⁴

DM2 is a common metabolic disorder caused by the inability of insulin-sensitive tissues to respond appropriately to insulin. Defects in any of the mechanisms involved in its synthesis can lead to a metabolic imbalance responsible for the development of the disease more so when there is an inability of insulin-sensitive tissues to respond appropriately to insulin.⁵ DM has become a common serious threat with costly management however controllable. It has been found that proper management and control can be done through prevention, early detection, improved delivery of care, and better education for diabetes self-management.⁶

Poorly controlled DM2 is considered a significant public health problem and is associated with adverse outcomes.⁷ DM2 is a major risk factor for cardiovascular disease and microvascular complications.⁸ The prospect of insulin therapy disturbs patients' sense of self and their psychological

well-being. There is a high need to address the psychological insulin resistance in patients with DM2 for effective diabetic management.⁹ The reasons for patient unwillingness were injection anxieties, fear of needles, insufficient knowledge of insulin, feeling unable to cope with insulin, and concerns about out-of-pocket costs.⁹

Because of therapeutic inertia and the progressive nature of the disease, many need at least a basal insulin supplementation and insulin analogs.¹⁰ Many patients with DM2 refuse insulin therapy even when they require this modality of treatment. Exploring patients' concerns and beliefs about DM and insulin is crucial to assist physicians in delivering patient-centered care.¹¹ Early glycemic control leads to better outcomes, including a reduction in long-term microvascular and microvascular complications.¹² Therefore, we aimed to determine the willingness to start insulin therapy among insulin-naïve persons with DM at an urban regional referral hospital in Northern Uganda.

Methods

Study design

A facility-based, quantitative, cross-sectional study was conducted between June and August 2023 recruiting insulin-naïve type 2 diabetes mellitus (T2DM) patients attending routine health care at Gulu Regional Referral Hospital (GRRH),

Gulu, Uganda. We followed the Strengthening the Reporting of Observational Studies in Epidemiology Guidelines.

Study setting

The study was conducted in GRRH, located in northern Uganda in Gulu City. GRRH is a tertiary and a teaching Hospital serving Northern Uganda, with an estimated 2000 DM patients at the diabetic clinic. The clinic is run by a physician, medical officers, and intern doctors, with an additional workforce being derived from a pool of general and specialized nurses, lab technologists, nutritionists, and social workers. The diabetes clinic receives patients with DM primarily from the Gulu district but also referral cases of complex patients for specialist review from across districts in Northern Uganda according to Uganda clinical guidelines.

Study population

The study participants were patients with physician-diagnosed DM2 who were, 18 years or older, attending outpatient DM clinics, and provided written informed consent to participate in the study. Participants who were admitted and unconscious or sedated with difficulty communication during the study period were excluded.

Sample size estimation

The sample size was estimated using the Kish–Leslie formula with the following assumptions: margin of error of 5%, at 95% confidence interval (CI), the prevalence of willingness modestly estimated at 50% since there was no previous study in Uganda about willingness to start insulin therapy, we obtain a minimum size of 384 and using Slovin's formula, a final sample size of 197 was realized.

Sampling procedure

We used a consecutive sampling technique to enroll eligible participants following their clinical reviews.

Data collection and tools

Data were collected using an interviewer-administered, structured questionnaire which was

adopted from Ngassa Piotie *et al.*⁹ The questionnaire was written in Luo and back translated in English. It was collected by trained research assistants with regular supervision. Socio-demographic characteristics such as age, sex, religion, marital status, clinical factors, attitudes are barriers to using insulin.

Operational definitions

Participants' willingness to utilize insulin was assessed through the question: 'If your physician were to prescribe insulin for your treatment, would you be willing to accept it?' with response options 'Yes' or 'No' indicating the participants' preferences.

For participants who responded 'No', a follow-up question was presented: 'Would you consider receiving insulin if it were the only treatment option?' A 'No' response to this follow-up question was categorized as indicative of hesitancy.

Statistical analysis

Data were entered into Microsoft Excel for coding and cleaning and exported to STATA version 18 for statistical analysis. Descriptive statistics of variables such as age, sex, and marital status were computed in frequency, percentage, median, mean, and standard deviation and presented using tables to show a picture of the data. Bivariate logistic regression was performed to determine each of the explanatory variables with the outcome variable (willingness) and variables with $p < 0.2$ during bivariate analysis were considered for further analysis to multivariable analysis. Poisson regression was conducted to determine the presence of a statistically significant association between explanatory variables and outcome variables because the prevalence of willingness was greater than 10%. Finally, variables with $p \leq 0.05$ were considered statistically significant, presented by adjusted prevalence ratio (aPR) with corresponding 95% CI.

Results

Socio-demographic characteristics

Of 296 participants screened, 106 were on insulin and were excluded and 190 were eligible. The mean age of the study participants was

Table 1. Socio-demographic characteristics of insulin naïve patients with type 2 diabetes attending diabetes clinic at Gulu Regional Referral Hospital, Gulu, Uganda.

Variable	Freq.	%
Age		
Mean (standard deviation)	55	12.72
<30	4	2.1
30–60	121	63.7
>60	65	34.2
Gender		
Male	57	30.0
Female	133	70.0
Education attainment		
Primary	84	44.2
Secondary	66	34.7
Tertiary	20	10.5
No schooling	20	10.5
Employment status		
Employed	30	15.8
Unemployed	160	84.2
Monthly household income, Ugandan Shillings		
Median (interquartile range)	50,000	50,000–150,000
<10,000	4	2.2
10,000–100,000	132	72.5
100,000–1,000,000	44	24.2
>1,000,000	2	1.1
IUSD=3750 Ugandan shillings.		

55 ± 12.72 years. Most participants were female (63.7%, $n=121$), attained a primary level of education (70.0%, $n=133$), and were unemployed (84.2%, $n=160$). The median household income was 50,000 Ugandan Shillings (UgX) [interquartile range (IQR): 50,000–150,000; 1 USD = 3750 UgX]. In total, 72.5% ($n=132$) of the participants earn a monthly household income between 10,000 and 100,000 UgX per month (Table 1).

Clinical characteristics

Overall, 38.5% ($n=70$) of the participants had diabetes for a period of 1–3 years, 37.0% ($n=70$) have had treatment for 1–3 years. In total, 91.0% ($n=122$) had hypertension and 8.3% ($n=11$) had HIV. For treatment, 70.6% ($n=132$) were on a combination of glibenclamide and metformin for DM treatment and 91.7% ($n=121$) on high blood pressure treatment. About 37.6% ($n=71$) visited the clinic every month and 71.5% ($n=133$) had never been advised about insulin (Table 2).

Willingness to start insulin therapy

Overall, 73.4% ($n=138$) of the participants were willing to commence insulin therapy if indicated. However, 15.3% ($n=29$) were hesitant.

Attitudes toward insulin use

The study participants expressed concerns about receiving daily injections (70.0%, $n=133$), fear of needles ($n=130$, 68.8%), coping with the demands of insulin therapy ($n=131$, 69.0%), and feeling like a failure when starting insulin ($n=116$, 61.1%) (Table 3).

Barriers to insulin use

Regarding barriers to insulin use among insulin-naïve DM2 patients who are willing or hesitant to start insulin therapy; 70.4% ($n=133$) do not have enough information regarding insulin; 66.7% ($n=126$) fear needles and the pain from injections; and 63.5% ($n=120$) are worried that they might forget to take the injections (Table 4).

Factors associated with willingness to start insulin therapy

Factors independently associated with willingness to start insulin therapy were diabetes duration of 6 years or more (aPR: 0.57, 95% CI: 0.39–0.81, $p=0.002$), those ever been advised recently on insulin (aPR: 1.34, 95% CI: 1.06–1.72, $p=0.007$) and those worried about coping up with the demands of insulin therapy (aPR: 0.45, 95% CI: 0.27–0.73, $p<0.001$) (Table 5).

Discussion

The current study investigated the willingness to initiate insulin therapy among insulin-naïve individuals with DM2 at GRRH in Uganda. Our

Table 2. Clinical characteristics of insulin-naïve patients with type 2 diabetes attending diabetes clinic at Gulu Regional Referral Hospital, Gulu, Uganda.

Variable	Frequency	Percentage
Diabetes duration, years		
Median (interquartile range)	4	2–8
>1	12	6.3
1–3	70	36.8
4–6	47	24.7
>6	61	32.1
Treatment duration		
Median (interquartile range)	4	2–8
>1	11	5.8
1–3	70	37.0
4–6	47	24.9
>6	61	32.3
Current diabetes treatment		
Glibenclamide	10	5.4
Metformin	34	18.1
Glibenclamide and metformin	132	70.6
Others	11	5.9
Other regular medicines		
Anti-hypersensitive	121	91.7
HIV treatment	11	8.3
Other	4	3.0
How often do you come for clinic visits?		
Every month	71	37.6
Every 2 months	56	26.6
Every 3 months	60	31.8
More than 3 months	2	1.1
Do you have a comorbidity?		
Yes	136	71.6
No	54	28.4
Do you have any diabetes complications?		
Yes	173	91.1
No	17	8.9
Ever been advised insulin in the past		
Yes	53	28.5
No	133	71.5

findings indicate that more than three-quarters of participants expressed willingness to commence insulin therapy, with only 15% displaying hesitancy. Furthermore, a longer duration of DM and concerns about coping with insulin therapy were associated with lower willingness, while recent physician advice on insulin was linked to increased willingness. These findings highlight the need for tailored interventions addressing specific concerns to enhance insulin acceptance in this population.

Our observed high willingness to commence insulin in Uganda is in line with a study carried out in South Africa where about 48% of the study participants expressed a willingness to start insulin therapy.⁹ In that study, 52% of the participants who were unwilling to start insulin, had negative attitudes, reluctance, injection anxieties, fear of needles, insufficient knowledge of insulin, feeling unable to cope with insulin, and concerns about out-of-pocket costs related to insulin treatment. A study conducted in Iran also showed that more than half of the participants were unwilling to start insulin therapy because they did not have enough knowledge about insulin efficacy and manifested inadequate knowledge about diabetes.¹³ Denial of the severity of the disease and denial of the failure of oral agents were the main reasons for refusing insulin therapy among patients.¹⁴

In our study, among the factors independently associated with willingness to start insulin therapy were those ever been advised recently on insulin and those worried about coping with the demands of insulin therapy. Similar findings were obtained in the study from South Africa⁹ where the majority of the respondents (84.8%) said that they had never been advised to take insulin. Patients' belief that injecting insulin is embarrassing was a reason for their delaying initiation of insulin therapy, thus highlighting the importance of injection stigma and how it affects the proper treatment of diabetes.¹⁵ On the other hand, a family history of insulin use increased the patient's willingness to start insulin. It seems that the presence of another family member using insulin can help overcome the barriers and increase the patient's willingness to start insulin therapy.¹⁶

We found that a longer duration of DM2 treatment with oral agents was associated with a 34%

Table 3. Attitude toward insulin of insulin-naïve patients with type 2 diabetes attending diabetes clinic at Gulu Regional Referral Hospital, Gulu, Uganda.

Attitude probe	Freq.	%
How do you feel about the following?		
Must take injections every day		
Not worried	57	30.0
Worried	133	70.0
I am afraid of needles		
Not worried	59	31.2
Worried	130	68.8
I feel like I cannot do the things I like to do		
Not worried	64	33.9
Worried	125	66.1
I have to cope with the demands of insulin therapy		
Not worried	59	31.1
Worried	131	69.0
I can't go out with friends and family		
Not worried	78	41.1
Worried	112	59.0
Going on insulin makes me feel like a failure		
Not worried	74	39.0
Worried	116	61.1

lower willingness to commence insulin therapy. The difficulties in fulfilling daily responsibilities and difficulties with injecting the right amount of insulin negatively affect motivation to use insulin. According to a study by Abu Hassan *et al.*,¹¹ about half of the patients with poor control T2DM did not timely start insulin therapy and the initiation was usually 3–5 years after failure of oral hypoglycemic agents. There are many factors influencing delayed insulin initiation including those caused by healthcare providers and its system, as well as the patients themselves.¹⁷

In this study, more than half of the participants could not afford to change their diet and have

regular meals. Insulin therapy comes in when there is a proven failure of dietary and lifestyle modifications together with glucose-lowering agents in the achievement of adequate glycemic control.¹⁰ Therefore, the basal insulin dose in conjunction with oral therapy is widely used to initiate insulin therapy, though, even when fasting hyperglycemia is under control, it is necessary to control post-prandial hyperglycemia to achieve target HbA1c levels.¹⁸ According to a study by Bzowycykj and Begert,¹⁹ the factors that led to therapeutic inertia related to patients' medication experiences such as the concerns about medication side effects and treatment costs, society-attached stigma, confusion about frequent changes in evidence-based guidelines, low health literacy, and social determinants of health.¹²

We also found out that 68% of participants had a fear of needles. Similarly in a study by Abu Hassan *et al.*,¹¹ majority of participants were reluctant to use insulin due to their negative concerns about insulin injection. This anxiety related to fear of injection pain or needles is very common among diabetics, reported to be more than half among insulin-naïve diabetics; thus, the use of thinner and shorter needles could reduce this fear, making injection less painful.¹⁶ However, a substantial proportion of diabetes patients who were treated with insulin naïve (43%) using thinner needles still admitted 'Injecting insulin is painful'.¹⁵

One particularly interesting finding of our study was that 70.4% do not have enough information regarding insulin. Similarly, participants with lower compared to higher educational levels had uncertainty about the efficacy of insulin therapy.¹⁵ These findings are based on the fact that patients with low and high education levels had little knowledge about diabetes and its treatment.⁹

Our study has some limitations. It was a single-center study, conducted in a regional referral hospital, with a relatively small sample size and findings cannot be generalized to all Ugandan patients with DM2 attending various primary healthcare facilities. This was minimized by carefully selecting a representative sample that adequately reflects the demographic and clinical characteristics of these participants. Future research endeavors should consider longitudinal designs and diverse healthcare settings to validate

Table 4. Barriers to insulin use among insulin-naïve patients with type 2 diabetes attending diabetes clinic at Gulu Regional Referral Hospital, Uganda.

Variable	Frequency	Percentage
I may be reluctant to start insulin treatment despite a doctor's recommendation because . . .?		
I don't have enough information regarding insulin		
No	56	29.3
Yes	133	70.4
I don't believe that insulin can help to control my diabetes		
No	116	61.1
Yes	74	39.0
I don't have enough financial resources to afford glucose meter and strips		
No	78	41.5
Yes	110	58.5
I cannot afford to change my diet and have regular meals		
No	90	47.4
Yes	100	52.6
Fear of needles and the pain of injections		
No	63	33.3
Yes	126	66.7
I am worried that I might forget to take my injections		
No	69	36.5
Yes	120	63.5
I am concerned about gaining weight		
No	106	56.1
Yes	83	43.9
I am worried about low blood sugar (hypoglycemia) due to insulin		
No	76	40.0
Yes	114	60.0
I have seen people deteriorate after they started insulin		
No	116	61.7
Yes	72	38.3
I have heard many negative things from people about insulin		
No	122	64.9
Yes	66	35.1
I will not be able to manage with insulin therapy		
No	82	43.2
Yes	108	56.8
I don't have any support at home to help me		
No	97	51.1
Yes	93	49.0

Table 5. Multivariate analysis of factors associated with willingness to start insulin therapy among insulin-naïve patients with type 2 diabetes attending diabetes clinic at Gulu Regional Referral Hospital.

Variable	Willing to start insulin		PR (95% confidence interval)	p Value
	No, n=50 Freq. (%)	Yes, n=138 Freq. (%)		
Age				
Mean (standard deviation)	60 (48–65)	54 (46–63)		
<30	0 (0.0)	4 (2.9)	Reference	Reference
30–60	27 (54.0)	93 (67.4)	1.09 (0.66–1.80)	0.740
>60	23 (46.0)	41 (29.7)	0.87 (0.52–1.45)	0.595
Education attainment				
No formal	9 (18.0)	11 (7.9)	Reference	
Primary	19 (38.0)	63 (45.7)	0.95 (0.73–1.21)	0.658
Secondary	13 (26.0)	53 (38.4)	0.88 (0.57–1.37)	0.599
Tertiary	9 (18.0)	11 (7.9)	0.67 (0.40–1.15)	0.152
Diabetes duration, years				
Median (interquartile range)	7.5 (3–10)	4 (2–6)		
<1	2 (4.0)	10 (7.3)	Reference	Reference
1–3	13 (26.0)	56 (40.6)	1.06 (0.77–1.46)	0.710
4–6	6 (12.0)	41 (29.7)	1.03 (0.73–1.43)	0.875
>6	29 (58.0)	31 (22.5)	0.57 (0.39–0.81)	0.002
Do you have complications?				
Yes	43 (86.0)	128 (92.7)	Reference	Reference
No	7 (14.0)	10 (7.3)	0.90 (0.63–1.30)	0.585
Ever been advised insulin in the past				
Yes	9 (18.8)	43 (31.6)	1.34 (1.06–1.72)	0.007
No	39 (81.3)	93 (68.4)	Reference	Reference
Have to take injections every day				
Not worried	8 (16.0)	48 (34.8)	Reference	Reference
Worried	42 (84.0)	90 (65.2)	0.83 (0.54–1.27)	0.406
I am afraid of needles				
Not worried	8 (16.0)	50 (36.5)	Reference	Reference
Worried	42 (84.0)	87 (63.5)	2.10 (0.98–4.49)	0.054

(Continued)

Table 5. (Continued)

Variable	Willing to start insulin		PR (95% confidence interval)	p Value
	No, n=50 Freq. (%)	Yes, n=138 Freq. (%)		
I feel like I cannot do the things I like to do				
Not worried	8 (16.0)	55 (40.2)	Reference	Reference
Worried	42 (84.0)	82 (59.9)	0.96 (0.54–1.71)	0.904
I have to cope with the demands of insulin therapy				
Not worried	6 (12.0)	52 (37.7)	Reference	Reference
Worried	44 (88.0)	86 (62.3)	0.45 (0.27–0.73)	0.001
I can't go out with friends and family				
Not worried	11 (22.0)	66 (47.8)	Reference	Reference
Worried	39 (78.0)	72 (52.2)	0.59 (0.31–1.11)	0.104
Going on insulin makes me feel like a failure				
Not worried	11 (22.0)	62 (44.9)	Reference	Reference
Worried	39 (78.0)	76 (55.1)	1.37 (0.65–2.88)	0.340

and expand upon the current findings, providing a more comprehensive understanding of the factors influencing insulin therapy acceptance in individuals with DM2. The high burden of complications of DM2 among the study participants merits further studies into the quality of DM care in this tertiary facility. We also recommend comparative studies investigating glycemic control and rates of complications in primary care facilities compared with our findings from tertiary care settings to further advanced best practices in diabetes care across the lifespan.

Conclusion

In conclusion, we found that over three-quarters of participants demonstrated a willingness to commence insulin therapy, contrasting with only 15% displaying hesitancy. Notably, a longer duration of diabetes and concerns about coping with insulin therapy were associated with diminished willingness, while recent physician advice on insulin correlated with increased willingness. Future interventions should prioritize addressing specific barriers related to prolonged disease duration and apprehensions about insulin therapy to optimize glycemic control in this population.

Declarations

Ethics approval and consent to participate

Ethical clearance and approval were sought from the Gulu University Research and Ethics Committee (GUREC-2022-459) and administrative clearance from the Gulu RRH administration. Informed consents were sought from the participants before administering questionnaires after explaining the aims and objectives of the study to the participants. Assurance was given to all the participants that all information was collected from and treated confidentially throughout the study. Helsinki protocol for the conduct of research was followed.

Consent for publication

All participants provided informed consent including consent to have their data published in scientific meetings and peer-reviewed publications.

Author contributions

Brenda Nakitto: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Software; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Moses Opedo: Conceptualization; Data curation; Methodology; Writing – original draft; Writing – review & editing.

Federes Nansubuga: Conceptualization; Data curation; Investigation; Methodology; Writing – original draft; Writing – review & editing.

Edward Omondi: Conceptualization; Data curation; Investigation; Methodology; Writing – original draft; Writing – review & editing.

Emmanuel Musunguzi: Conceptualization; Data curation; Methodology; Writing – original draft; Writing – review & editing.

Edwin Cleopas Otile: Conceptualization; Data curation; Investigation; Methodology; Writing – original draft; Writing – review & editing.

Steven Ekak: Investigation; Writing – original draft; Writing – review & editing.

Christine Nannungi: Writing – original draft; Writing – review & editing.

Paska Apiyo: Conceptualization; Investigation; Methodology; Writing – original draft; Writing – review & editing.

Pebalo Francis Pebolo: Conceptualization; Data curation; Formal analysis; Methodology; Resources; Supervision; Writing – original draft; Writing – review & editing.

Felix Bongomin: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Acknowledgements

We acknowledge all the study participants for their valuable time and support in completing the study.

Funding

The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: Felix Bongomin is HBNU consortium Fogarty Global Health Fellow, and his work is supported by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW010543. The content is solely the responsibility of the

authors and does not necessarily represent the official views of the National Institutes of Health.

Competing interests

The authors declare that there is no conflict of interest.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID iD

Felix Bongomin  <https://orcid.org/0000-0003-4515-8517>

Supplemental material

Supplemental material for this article is available online.

References

1. Chatterjee S, Khunti K and Davies MJ. Type 2 diabetes. *Lancet* (London, UK) 2017; 389: 2239–2251.
2. Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. *Future Cardiol* 2018; 14: 491–509.
3. Zheng Y, Ley SH and Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018; 14: 88–98.
4. Ojuka EO and Goyaram V. Increasing prevalence of type 2 diabetes in sub-Saharan Africa: not only a case of inadequate physical activity. *Med Sport Sci* 2014; 60: 27–35.
5. Galicia-Garcia U, Benito-Vicente A, Jebari S, *et al.* Pathophysiology of type 2 diabetes mellitus. *Int J Mol Sci* 2020; 21: 6275.
6. DeCoste KC and Scott LK. Diabetes update: promoting effective disease management. *AAOHN J* 2004; 52: 344–353; quiz 354–355.
7. Al-Sahouri A, Merrell J and Snelgrove S. Barriers to good glycemic control levels and adherence to diabetes management plan in adults with type-2 diabetes in Jordan: a literature review. *Patient Prefer Adherence* 2019; 13: 675–693.
8. Alatawi YM, Kavookjian J, Ekong G, *et al.* The association between health beliefs and medication

- adherence among patients with type 2 diabetes. *Res Social Adm Pharm* 2016; 12: 914–925.
9. Ngassa Piotie P, Wood P, Webb EM, *et al.* Willingness of people with type 2 diabetes to start insulin therapy: evidence from the South African Tshwane Insulin Project (TIP). *Diabetes Res Clin Pract* 2020; 168: 108366.
 10. Aschner P. Insulin therapy in type 2 diabetes. *Am J Ther* 2010; 27: e79–e90.
 11. Abu Hassan H, Tohid H, Mohd Amin R, *et al.* Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. *BMC Fam Pract* 2013; 14: 164.
 12. Khunti S, Khunti K and Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. *Ther Adv Endocrinol Metab* 2019; 10: 2042018819844694.
 13. Swinnen SG, Hoekstra JB and DeVries JH. Insulin therapy for type 2 diabetes. *Diabetes Care* 2009; 32(Suppl_2): S253–S259.
 14. Olokoba AB, Obateru OA and Olokoba LB. Type 2 diabetes mellitus: a review of current trends. *Oman Med J* 2012; 27: 269–273.
 15. Rajab A, Khaloo P, Rabizadeh S, *et al.* Barriers to initiation of insulin therapy in poorly controlled type 2 diabetes based on self-determination theory. *East Mediterr Health J* 2020; 26: 1331–1338.
 16. Feher MD, Brazier J, Schaper N, *et al.* Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes. *BMJ Open Diabetes Res Care* 2016; 4: e000192.
 17. Gameda ST and Woldemariam ZB. Assessment of self-care practice amongst patients with type II diabetes attending Adama Hospital Medical College, Ethiopia. *BMC Endocr Disord* 2022; 22: 1–10.
 18. Raccach D, Bretzel RG, Owens D, *et al.* When basal insulin therapy in type 2 diabetes mellitus is not enough – what next? *Diabetes Metab Res Rev* 2007; 23: 257–264.
 19. Bzowycyk AS and Begert JE. Diabetes, therapeutic inertia, and patients' medication experience. *Diabetes Spectr* 2020; 33: 31–37.

Visit Sage journals online
journals.sagepub.com/
home/taj

 Sage journals